Real-World data may reveal best Second-Line therapy for multiple myeloma
NCT ID NCT07689006
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study looks back at medical records of over 300 adults with relapsed/refractory multiple myeloma to compare how well different drug combinations work in everyday practice. Researchers are analyzing outcomes like how long patients live without their cancer worsening and overall survival for those who received pomalidomide-based treatments versus other standard therapies. The goal is to see which approach may offer better results after initial treatments stop working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pomalidomide (in combination with other drugs)
- What this could lead to
- If pomalidomide-containing regimens show better outcomes, this could help doctors choose more effective treatments for patients with relapsed/refractory multiple myeloma.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient differences. It does not prove one treatment is better than another.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OneOncology Network
Nashville, Tennessee, 37219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody combo aims to stall multiple Myeloma's return
- New universal cell therapy shows promise for Hard-to-Treat blood cancer
- Experimental NK cell therapy for blood cancers hits early hurdle
- New CAR-T therapy RN9101 targets Hard-to-Treat myeloma
- Vitamin c boost: could it make chemo safer for myeloma patients?
- Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?